Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGF816 or INC280 with Nivolumab in NSCLC
NCT02323126Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2015
- Primary completion
- Sep 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 8
01
Overview
Phase 2, open-label trial of nazartinib and capmatinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoint: Progression-Free Survival Rate at 6 Months. Started Feb 2015; status: terminated.
02
Drugs
nazartinibcapmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02323126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323126.